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Dr. Subotića 4, 11129 Belgrade, Serbia
Correspondence should be addressed to Juan Francisco Santibañez; jfsantibanez@imi.bg.ac.rs
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Interleukin 17 (IL-17) is a cytokinewith pleiotropic effects associatedwith several inflammatory diseases. Although elevated levels of
IL-17 have been described in inflammatory myopathies, its role in muscle remodeling and regeneration is still unknown. Excessive
extracellular matrix degradation in skeletal muscle is an important pathological consequence of many diseases involving muscle
wasting. In this study, the role of IL-17 on the expression of matrix metalloproteinase- (MMP-) 9 in myoblast cells was investigated.
The expression ofMMP-9 after IL-17 treatmentwas analyzed inmousemyoblastsC2C12 cell line.The increase inMMP-9production
by IL-17 was concomitant with its capacity to inhibit myogenic differentiation of C2C12 cells. Doxycycline (Doxy) treatment
protected themyogenic capacity of myoblasts from IL-17 inhibition and,moreover, increasedmyotubes hypertrophy. Doxy blocked
the capacity of IL-17 to stimulateMMP-9 production by regulating IL-17-induced ERK1/2 MAPK activation. Our results imply that
MMP-9 mediates IL-17’s capacity to inhibit myoblast differentiation during inflammatory diseases and indicate that Doxy can
modulate myoblast response to inflammatory induction by IL-17.
1. Introduction
Interleukin 17 (IL-17) family of cytokines has been intensively
investigated in recent years. As a proinflammatory cytokine,
IL-17 is involved in immune defense mechanisms acting
through induction of secondary mediators of inflammation.
However, its implication in various human inflammatory
diseases such as rheumatoid arthritis and myositis was also
demonstrated [1–3].
A number of data confirm the pleiotropic nature of
IL-17. Its receptor (IL-17R) is ubiquitously expressed, in
almost all cell types, allowing the widespread influence of
IL-17 on cellular processes, through subsequent activation
of numerous signal transduction pathways, such as protein
kinase A, JAK/STAT, NF-𝜅B, and MAPKs, including ERK1/2
and p38 cascades [4, 5].
Proinflammatory cytokines are considered important
mediators of skeletal muscle loss in various chronic dis-
eases [6]. Known to be associated with the development
of inflammatory diseases, IL-17 has also been implicated in
myopathies, such as polymyositis and dermatomyositis [7,
8]. However, its role in muscle repair or regeneration has
not been clarified yet. Skeletal muscle repair depends on
satellite cells present in situ. These cells have the capability
to proliferate, migrate to sites of injury, and differentiate
into adult muscle cells [9]. During this process, the extra-
cellular matrix (ECM) is dynamically and finely remod-
eled, while the imbalance in ECM reorganization can be
involved in the development of muscle diseases [10]. Matrix
metalloproteinases (MMPs) are a family of enzymes which
can selectively digest individual components of the ECM
[10, 11]. Several MMPs have been shown to be implicated
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in muscle regeneration, including matrix metalloproteinase
type 2 (MMP-2) and matrix metalloproteinase type 9 (MMP-
9). In skeletal muscle, MMP-2 is constitutively expressed,
whereas MMP-9 shows none to minimal basal expression
[10, 11]. In particular, MMP-9 expression and/or activity are
tightly transcriptionally regulated and highly inducible in
response to variety of agents, including proinflammatory
cytokines [12]. In addition, increased expression and acti-
vation of MMP-9 are associated with various myopathies
and inflammation-induced changes in skeletal muscle [10].
Moreover, the upregulation of MMP-9 expression has been
described in the muscles of mdx mice, an animal model
of Duchenne muscular dystrophy [13]. Even though high
expression of both IL-17 and MMP-9 has been reported
in inflammatory myopathies, the mutual relation of these
proteins in muscle is still not well understood.
Doxycycline (Doxy) is an antibiotic of the tetracycline
family of drugs and has been tested in numerous conditions
associated with elevated MMP activity [14]. It has recently
been demonstrated that Doxy can be beneficial for mdx mice
mainly by reducing MMP-9 and TNF-𝛼 expression [15]. It
was also demonstrated that Doxy or anti-MMP-9 antibody
improves soleus muscle regeneration and ameliorate devel-
opment of excessive fibrosis [16]. In addition, recent work
showed that Doxy treatment can regulate both local and
systemic inflammation, suggesting its importance in inflam-
matory myopathies [17, 18]. We have recently demonstrated
the ability of IL-17 to inhibit myogenesis in vitro [19], while
MMP-9 participation as well as the regulatory role of Doxy
in this process has not been well defined so far.
Our findings indicate that IL-17 increases MMP-9 expres-
sion, along with the inhibition of C2C12 myoblast differen-
tiation. Furthermore, results presented here show that Doxy
protects C2C12myoblasts from the capacity of IL-17 to inhibit
myogenesis.
2. Material and Methods
2.1. Cell Culture. Myoblast C2C12 cell line was purchased
from American Type Culture Collection (ATCC, Rockville,
MD). Cells were cultured in growthmedium (GM) consisting
of Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% Fetal Bovine Serum (FBS) from Capricorn
Scientific (Ebsdorfergrund, Germany) and 100 Units/mL
Penicillin and 0.1 mg/mL Streptomycin (Capricorn Scientific)
in a humidified environment at 37∘C and 5% CO
2
in air.
Myogenic differentiation was induced by culturing confluent
cells in myogenic differentiation medium (MDM) consisting
of GM supplemented with 2% horse serum instead of 10%
FBS.
Recombinant mouse IL-17 was provided by R&D Systems
(Minneapolis, MN, USA). Doxycycline was from Sigma-
Aldrich (St. Louis, MO, USA). MEK1,2 inhibitor PD98059
was obtained from Calbiochem (Darmstadt, Germany) and
used at 25𝜇M.
2.2. Zymography Assay. MMP-9 and MMP-2 activities
were examined as described previously [20]. Briefly,
50.000 cells/well were seeded in 24-well plates and cultured
overnight; then, the cells were washed three times with
PBS and 0.5mL of serum-free culture medium was added.
Cells were subsequently cultured with or without IL-17
as indicated for each experiment. During the induction
of myogenic differentiation, cells were cultured for three
days in MDM and additional 24 h to generate conditioned
serum-free medium for MMP-9 determination. Protein
concentration in conditioned media was determined by
BCA Protein Assay Macro Kit (Serva, Heidelberg, Germany)
according to manufacturer’s instructions. Aliquots of
protein normalized conditioned media were subjected to
8% SDS-PAGE containing 0.1% gelatin under nonreducing
conditions. Gels were washed twice with 2.5% Triton X-100
and rinsed one time with distilled H
2
O. The gels were then
incubated for 24 hours in 100mM Tris-HCl, pH 8.5, with
10mM CaCl
2
. The activity of MMPs was stopped by staining
the gels with Coomassie Blue R250 in 50% methanol and
10% acetic acid for 20 minutes. Zymography was developed
by destaining gels in 20% methanol and 5% acetic acid
until transparent bands were visualized. Quantification of
these areas was performed by densitometry analysis using
NIH-Image J software.
2.3. Myotube Hypertrophy Index. C2C12 cells were grown
in 24-well plates until reaching 90% confluence and then
subjected to myogenic differentiation by replacing GM with
MDM. Cells were cultivated for 4 days with indicated treat-
ments. Cell monolayers were washed twice with PBS and
fixed with ice cold methanol for 2min, then stained with
crystal violet (0.1%) for 15min, and extensively washed with
tap water. This strongly stained myotubes and nuclei within.
To determine the hypertrophy index, myotube diameter was
determined according to Yeh et al. [21]. Cultured cells were
photographed using 10x objective lens and NIH-Image J
software was used to measure myotube diameter. At least, 50
myotubes were used to determine the diameters and 3 short-
axis measurements were taken along the length of a given
myotube diameter and the average was calculated.
2.4. Western Blot Assay. Protein expression was analyzed
by Western blot assay. Antibodies against myosin heavy
chain (MyHC), phospho-ERK1/2 (sc-7383), and ERK1 (sc-
94) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Mouse monoclonal anti-HA antibody was
kindly provided by Dr. Carmelo Bernabeu (CIB, Spain).
Cells were lysed in lysis buffer (50mM Tris-HCl, pH 7.5,
150mM NaCl, 1% NP-40) containing 2mM EDTA, 50mM
NaF, and protease inhibitor cocktail (SERVA Electrophoresis
GmbH, Heidelberg, Germany). Equal amounts of protein
from each sample were separated by SDS-PAGE and trans-
ferred to nitrocellulose membranes (AppliChem, Darmstadt,
Germany). Membranes were blocked with 4% BSA in 0.5%
Tween-20 in TBS and then incubated with primary antibod-
ies.Membraneswere then incubatedwith secondary antibod-
ies conjugated with HRP (Sigma-Aldrich). Labeled proteins
were visualized using enhanced chemiluminescence reagent
system from AppliChem. Protein bands were quantified by
densitometry scanning, using NIH-Image J software and
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expressed relative to tubulin or corresponding total protein
signals.
2.5. RT-PCR. Two micrograms of total RNA isolated from
C2C12 cells was reverse transcribed using Superscript II
(Invitrogen). PCRs were performed using One-Step PCR
(Invitrogen) with the following settings: 94∘C for 5min,
26–30 cycles at 94∘C for 45 sec, 52–54∘C for 30 sec, and
72∘C for 90 sec. The primer sets, annealing temperatures,
number of cycles, and product size for each gene are given in
Supplementary Table 1 (in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/2939658) [22, 23].
Amplicons were resolved in 1.5% agarose gel stained with
ethidium bromide. The intensity of the bands was quantified
using NIH-Image J software.
2.6. Plasmids, Transient Transfection, and Reporter Assays.
The reporter construct pMMP-9-luc containing 1300 bp of
the 50-flanking region of the mouse MMP-9 gene has been
previously described [20]. Mousemyogenin promoter (G133-
luc) was kindly provided by Dr. Zhenguo Wu (Hong Kong
University of Science & Technology, Hong Kong, China).
G133-Luc and its derivatives were generated by inserting
the XbaI-BglII fragments from the corresponding chlo-
ramphenicol acetyltransferase constructs into the HindIII-
BglII-digested pXP2, respectively [24]. ERK1/2 signaling was
determined using pSRE-Luc (kindly provided by Dr. A.
Corbi, CIB, Madrid, Spain), which contains two copies of
the c-fos SRE (nucleotides −357 to −275, containing both
an SRF binding site and an adjacent Ets motif) upstream
of a minimal Tk promoter and the luciferase gene. PCMV-
𝛽-galactosidase expression vector was kindly provided by
Dr. C. Bernabeu (CIB, Spain) and was used as a positive
control for transfection efficiency. Constitutively active and
dominant-negative MEK1-HA tagged constructs were kindly
provided by Dr. Jacques Pouyssegur (University of Nice-
Sophia Antipolis, France). The constitutively active mutant
of MEK1 (CA-MEK1) was designed by substitution of the
regulatory phosphorylation sites, Ser218 and Ser222, with
aspartic acid (S218D/S222D mutant) as described previously
[25]. The pcDNA3.1 empty vector was from Invitrogen.
C2C12 myoblasts seeded in 24-well plates (2 ×
105 cells/well) were transfected with different plasmids using
Turbofect transfection reagent according to the manu-
facturer’s protocol (Fermentas, St. Leon-Rot, Germany).
After 24 hours of treatment, cells were lysed with 50𝜇L of
passive lysis reagent and firefly luciferase activity (Promega,
Madison,WI, USA) was determined. 𝛽-galactosidase activity
(Tropix, Bedford, MA, USA) was measured as an internal
control for transfection efficiency.
2.7. Statistical Analysis. All experiments were performed at
least three times and representative results are shown. Data
are given as means ± SEM. Statistical significance was evalu-
ated using one-way ANOVA followed by Tukey’s test between
individual groups. Differences were considered significant at
a value of 𝑝 < 0.05 (∗) and 𝑝 < 0.001 (∗∗) between control
samples and treated samples. Differences were considered
significant at values 𝑝 < 0.001 (##) between IL-17-treated
samples and Doxycycline plus IL-17-treated samples.
3. Results
3.1. IL-17 Increases MMP-9 Production in Myoblast Cells.
Firstly, we examined whether IL-17 can regulate the expres-
sion and production ofMMP-9, amajor extracellular protease
that can degrade several components of basement membrane
and intramuscular connective tissue [26], in cultured C2C12
myoblasts. C2C12 cellswere incubated in serum-freemedium
with increasing amounts of IL-17 for 24 hours and the
production of MMP-9 in culture supernatants was mea-
sured by gelatin zymography. The treatment with increasing
amounts of IL-17 significantly enhanced the activity ofMMP-
9 and increased MMP-9 mRNA levels (Figure 1(a)), while
it did not produce detectable changes in MMP-2 activity
(Supplementary Figure 1(a)). Next, we evaluated the effect of
IL-17 on the transactivation of MMP-9 promoter in C2C12
cells. Similar to the results obtained in zymography assay
and RT-PCR, IL-17 increased the transactivation of MMP-9-
specific promoter in a dose-dependent manner (Figure 1(b)).
3.2. MMP-9 Production Is Highly Induced by IL-17 during
Inhibition of C2C12 Myogenic Differentiation. To determine
whether IL-17 affects MMP-9 expression during myogenic
differentiation, C2C12 cells were induced to differentiate
under IL-17 treatment and MMP-9 expression was deter-
mined after three days. As presented in Figure 2(a), both in
GM and under differentiation induction, increased MMP-9
production and expression were noticed in response to IL-
17 treatment, as determined by both zymography and RT-
PCR. Moreover, during C2C12 differentiation induction, IL-
17 inhibited the expression of myogenesis markers myosin
heavy chain (MyHC) and muscle creatine kinase (MCK),
determined by Western blot and RT-PCR, respectively (Fig-
ure 2(b)), suggesting that IL-17 induces MMP-9 expression
concomitantlywith the inhibition ofmyogenic differentiation
of C2C12 cells. The enhanced MMP-9 and reduced MCK
expression paralleled with the myotubes atrophy induced by
IL-17, as shown in Supplementary Figure 1(b).
3.3. Doxycycline Reverts Myogenesis Inhibition Induced by IL-
17. Modulation of MMP-9 is beneficial for the improvement
of skeletal muscle regeneration in mdx mice [12, 16]. It has
been demonstrated that the MMP inhibitor Doxy decreases
the level of MMP-9 in biceps brachii and diaphragm of
the mdx mice [15]. Next, we aimed to elucidate whether
MMP-9 modulated by Doxy may protect C2C12 cells from
the inhibition of myogenesis induced by IL-17. The optimal
concentration for Doxy was set to 10𝜇g/mL after dose-
dependent experiment (data not shown). Doxy (10𝜇g/mL)
improved myogenesis (Figure 3(a)) by producing more
hypertrophic myotubes, determined by the average myotube
diameter (2.45-fold compared with cells grown in MDM
only). In addition, Doxy protected myotubes formation in
the presence of IL-17, as the cells had the hypertrophy index
similar to that in control. Interestingly, myotubes appeared

































































Figure 1: IL-17 enhances MMP-9 production in C2C12 myoblast cells. (a) C2C12 cells were treated with increasing concentrations of IL-17
for 24 h. MMP-9 activity in conditionedmedia was determined by zymography andMMP-9 expression was determined by RT-PCR analysis.
GAPDH was used as a gel loading control. MMP-9 activity is observed in form of clear bands in the gel. Quantification plot is presented
above the zymography. (b) MMP-9 promoter transactivity in C2C12 cells transiently transfected with mouse pMMP-9-luc reporter plasmid
and treated with increasing amounts of IL-17 for 24 h. Significant difference from the control (cells not treated with IL-17) by 𝑡-test: ∗𝑝 < 0.05
and ∗∗𝑝 < 0.001.
to be shorter in the presence of IL-17 than myotubes formed
without IL-17 treatment. The effect of Doxy was confirmed
by muscle-specific protein MyHC expression. As shown in
Figure 3(b), MyHC was highly expressed in the presence of
Doxy during myogenesis induction, while, in the presence
of IL-17, C2C12 cells expressed MyHC at similar levels
as cells cultivated in MDM only. Moreover, IL-17-induced
repression of the MCK gene expression (Figure 3(c)) was
completely conversed by Doxy as well as the IL-17-induced
repression of myogenin promoter (pG133-luc) transactivity
(Figure 3(d)).
3.4. Doxycycline Inhibits MMP-9 Induced by IL-17. Beyond
its capacity to inhibit MMP activity, Doxy has been
demonstrated to inhibit MMP-9 protein expression [27].
Next, we determined whether Doxy can transcriptionally
regulate IL-17-induced MMP-9 expression in C2C12 cells.
As shown in Figure 4(a), Doxy (5 or 10𝜇g/mL) inhibited
both basal MMP-9 expression levels and the capacity of IL-
17 to increase the secreted activity of MMP-9.This inhibition
seems to be due to transcriptional regulation, since Doxy
also reduced both promoter transactivation and MMP-9
mRNA expression induced by IL-17 (Figures 4(b) and 4(c)).





















































Figure 2: MMP-9 is highly induced by IL-17 during myogenic differentiation of C2C12 cells. (a) C2C12 cells were cultured in myogenic
differentiation medium (MDM) with or without 50 ng/mL of IL-17 and compared to cells cultured in GM with or without IL-17. MMP-9
activity in conditioned media was determined by zymography. MMP-9 mRNA transcript production in C2C12 cells was determined by RT-
PCR analysis. GAPDH was used as a gel loading control. Quantification plot is presented above the zymography. (b) MCK and MyHC
expression in C2C12 cells during myogenic differentiation with or without 50 ng/mL of IL-17 determined by RT-PCR and Western blot
analysis, respectively. 𝛼-tubulin and GAPDH were used as gel loading controls.
Moreover, similar Doxy concentrations did not signifi-
cantly modify MMP-2 secreted activity (Supplementary
Figure 1(c)).
3.5. Doxycycline Inhibits ERK1/2MAPKActivation Induced by
IL-17. Subsequent experiments addressed the involvement
of intracellular signaling pathways in IL-17-induced MMP-9
expression in C2C12 cells. We have previously shown that IL-
17 activates ERK1/2 in C2C12 cells [19], and, in order to clarify
whether ERK1/2 pathway mediates IL-17-induced MMP-9
production and expression, C2C12 cells were treated with IL-
17 in the presence of MEK1,2 inhibitor, PD98059, and the
MMP-9 protein and mRNA expression were determined. As
shown in Figure 5(a), cotreatment of the cells with IL-17 and
MEK1,2 inhibitor significantly blocked the increment of both
MMP-9 activity and mRNA expression induced by IL-17.
Furthermore, the IL-17-increased MMP-9-specific pro-
moter transactivation was dramatically inhibited by domi-
nant-negative (DN) MEK1 promoter, while the cotrans-
fection with constitutively active MEK1, independently of IL-
17, significantly transactivated the MMP-9 promoter (Fig-
ure 5(b)). ERK1/2 signaling appeared to be necessary and
sufficient to mediate IL-17-induced MMP-9 expression in
C2C12 cells. The appropriate expression of both dominant-
negative and constitutively active (Ca) mutants of MEK1 in
transiently transfected C2C12 cells was confirmed by their
reactivity to anti-HA antibody (Figure 5(c)). It has also been
shown that, independently of its capacity to inhibit MMP
activity, Doxy inhibits MAPK activation [27]. Since ERK1/2
signaling seems to be critical for IL-17’s induction of MMP-
9, we determined whether Doxy affects the activation of this
pathway by IL-17. As shown in Figure 5(d), the capacity of
IL-17 to induce ERK1/2 phosphorylation was dramatically
inhibited in the presence of Doxy (5 or 10𝜇g/mL).This result
paralleled with the transactivation capacity of this signal,
since Doxy inhibited the capacity of IL-17 to induce the trans-
activation of pSRE-luc reporter (Figure 5(e)), thus indicating
that Doxy inhibits IL-17-induced MMP-9 by downregulating
ERK1/2 signal transduction.
4. Discussion
Skeletal muscle repair is a highly synchronized process
involving various cellular and molecular responses. Coordi-
nation between inflammation and regeneration is believed to
be crucial for the beneficial outcome of the repair process






























































Figure 3: Doxycycline reverts myogenesis inhibition induced by IL-17. (a) Hypertrophy index of myotubes was measured after 4 days of
cultivation in differentiation medium with or without Doxy and IL-17. Hypertrophic myotubes are determined by the average myotube
diameter. (b) MyHC protein expression under conditions described above determined by Western blot. 𝛼-tubulin is used as gel loading
control. (c)MCK expression under conditions described above determined by RT-PCR. GAPDH is used as gel loading control. (d) Myogenin
promoter (pG133-luc) transactivity determined by luciferase assay. RLU: relative luciferase activity.
following muscle damage [28, 29]. During this process,
the extracellular matrix surrounding skeletal muscle cells
has an important role in maintaining the structure of the
muscle, acting as a scaffold for myofiber regeneration [10,
30]. Therefore, remodeling of ECM is important for muscle
maintenance and repair in normal and pathological condi-
tions. Matrix metalloproteinases are key players in skeletal
muscle ECM degradation and regeneration [10]. In addition
to high levels of IL-17, elevated levels ofMMP-9 have also been
observed in skeletal muscle during inflammatory myopathies
[10]. However, regulation of MMP-9 expression by IL-17 in
muscle cells has not been elucidated yet.
In the present work, our results demonstrated that IL-17
increases the expression and production of MMP-9 in mouse
myoblast cells C2C12, while not significantly affecting the
constitutively expressedMMP-2 (Figure 1 and Supplementary
Figure). Expression of MMP-2 and MMP-9 has been previ-
ously reported in myogenic cells of various species with a
general consensus about the constitutive expression ofMMP-
2 by muscle cells and more controversial MMP-9 expression
[31]. Our results obtained using C2C12 cells showed that
IL-17 increases MMP-9 expression at both transcriptional
and protein level. Since IL-17 is primarily a proinflamma-
tory cytokine, this result is in agreement with previous
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Figure 4: IL-17-stimulated MMP-9 expression is inhibited by Doxycycline. (a) IL-17 induced MMP-9 activation in the presence or absence
of 5 or 10𝜇g/mL of Doxy determined by zymography. (b) Promoter transactivation induced by IL-17 in the presence or absence of Doxy. (c)
IL-17-induced MMP-9 mRNA expression determined by RT-PCR. GAPDH is used as gel loading control.
observations that MMP-9 expression is related to the inflam-
matory response [10], as well as that MMP-9 upregulation in
muscle tissue appears to be a common finding in all inflam-
matory myopathies [31]. In addition, it is consistent with the
abundant evidence, indicating that MMP-9 gene expression
is, to a large extent, tightly regulated at transcriptional
level [32]. Furthermore, it is known that proinflammatory
cytokines are able to activate muscle satellite cells, possibly
by inducing MMP-9 expression [10].
During myogenic differentiation, basal MMP-9 expres-
sion was increased and its expression was higher in the pres-
ence of IL-17. This effect was accompanied with the capacity
of IL-17 to inhibit the expression of myogenic differentiation
marker MCK, demonstrating that IL-17 enhances MMP-9
expression concomitantly with the inhibition of myogenic
differentiation of C2C12 cells. It could be speculated that
chronic exposure to IL-17, by inducing MMP-9 expression,
may affect the homeostasis of muscle cells, as well as their
ECM remodeling, which could then contribute to the devel-
opment of inflammatory muscle diseases. In pathological
conditions, abnormal increment in MMP-9 expression and
activity may produce excessive degradation of type IV col-
lagen in the skeletal muscle basement membrane, which in
cooperation with other MMPs can lead to skeletal muscle
tissue loss [10, 33].
Doxycycline is themost potentMMP inhibitor among the
Food &Drug Administration USA/Health Canada-approved
tetracyclines, which inhibits MMP activity at plasma levels
lower than those needed for its antimicrobial effect [34, 35].
In addition, Doxy, beyond its role in proteolysis, possesses
biological roles in inflammation, angiogenesis, apoptosis,
metal chelation, ionophoresis, and bone metabolism [36].
Our results demonstrated that Doxy may rescue in vitro
myoblast differentiation by reverting IL-17 inhibition of
myogenesis and MMP-9 induction. Moreover, during the
induction of myoblastic differentiation, Doxy appeared to
increase myotube mass, indicated by the hypertrophic index
and MyHC expression. Interestingly, although MMP-9 inhi-
bition was shown to improve soleus muscle regeneration in
vivo, it has been reported by Zimowska et al. that Doxy may
delay C2C12 differentiation in vitro [16]. In the aforemen-
tioned study, authors used Doxy at concentration of 60 𝜇M
which is approximately three times higher than the highest
concentration utilized in this study (10𝜇g/mL or 22𝜇M). We
observed that 5 𝜇g/mL (11𝜇M) is enough to induce myotube
hypertrophy. This may indicate that the Doxy concentration
is important to achieve the desired effects, and higher con-
centration may impair myogenesis by excessive inhibition of
MMP-9, which is also necessary for normal myogenic differ-
entiation where MMP-9 is mainly secreted during prefusion
stages [10]. However, during inflammatory process, increased
MMP-9 secretion may disturb the proteolytic homeostasis,
thus impairing muscle cell differentiation, as observed here
for IL-17.


















































































































Figure 5: Doxycycline reduces MMP-9 expression by inhibiting IL-17-stimulated ERK1/2 activation in C2C12 cells. (a) MMP-9 expression
in C2C12 cells determined by zymography and RT-PCR. Cells were, in the presence or absence of PD98059 (25𝜇M), treated with or without
50 ng/mL IL-17 for 24 h. GADPHwas used as a gel loading control. Numbers represent average densitometry values over control with value 1.
(b) Cells were transiently transfected with mouse MMP-9 promoter and cotransfected with DNMEK1 or CaMEK1 mutants or cotreated with
PD98059 (25𝜇M). After the cells were treated for 24 h without or with IL-17 (50 ng/mL), luciferase activities were determined. Results are
presented over control with value 1. Significant differences from the control (cells not treated with IL-17) by 𝑡-test: ∗𝑝 < 0.05 and ∗∗𝑝 < 0.001.
(c) Expression of dominant-negative (DN) and constitutively active (Ca) mutants of MEK1 transiently transfected C2C12 cells was confirmed
by their reactivity to anti-HA antibody (d) IL-17-induced ERK1/2 phosphorylation in the presence or absence of Doxy (5 or 10 𝜇g/mL) was
determined by Western blot. (e) Transactivation of pSRE-luc reporter by IL-17 in the presence or absence of Doxy.
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As mentioned above, Doxycycline may also affect dif-
ferent biological processes which can be explained by its
capacity to influence the activation of intracellular signals
such as ERK1/2 signaling [27, 37]. In this line, IL-17 was
shown to trigger numerous signal transduction pathways,
including ERK1/2 and p38 MAPKs [4]. In accordance with
our previous work [19], we confirmed here that IL-17 is
able to enhance phosphorylation of ERK1/2 in C2C12 cells,
and we also showed that this pathway was essential for the
induction of MMP-9 expression by IL-17. Our results indicate
that Doxycycline strongly inhibits IL-17-induced MMP-9
expression and ERK1/2 activation. Furthermore, we demon-
strated that MEK1,2-ERK1/2 inhibition by using the chemical
inhibitor PD98059 reverted the suppressive effect of IL-17
on C2C12 myogenic differentiation [19]. Moreover, PD98059
was shown to enhance C2 myoblast cell differentiation in
vitro [38], thus suggesting that Doxy may rescue C2C12
myogenic differentiation by downregulating IL-17 activation
of ERK1/2 signaling which is necessary for the increased
MMP-9 expression.
Interestingly, IL-17 did not affect the capacity of C2C12
cells to secrete MMP-2, and similar result was obtained by
treating cells with Doxy (Supplementary Figure), indicating
thatMMP-2 is not a target gene neither for IL-17 nor forDoxy.
It has been demonstrated that during C2C12 differentiation
MMP-2 expression is mainly unaltered, since MMP-2 is
expressed in these cells by a constitutive mechanism [39,
40]. Although, in some inflammatory myopathies, such as
polymyositis, dermatomyositis, and inclusion body myositis,
both MMP-2 and MMP-9 are upregulated, their balance
depends on the type of disease and local presence of var-
ious factors. In this regard, upregulated MMP-9 in muscle
tissue appears to be a common finding in all inflammatory
myopathies, while MMP-2 seems to be affected to a lesser
extent [31]. Results presented here, together with our previ-
ously published results, which demonstrated that IL-17 does
not affect MMP-2 expression, while it inhibits the expression
of uPA in C2C12 cells [41], further confirm the complex role
that IL-17 has on proteolytic enzymes expression and activity
inmyoblasts. This suggested that MMP-9/MMP-2 disbalance
may be one of the major characteristics of myopathies.
Therefore, IL-17 may affect C2C12 myogenic differentiation
by increasing MMP-9 expression, while Doxy can protect
and preserveMMP-9/MMP-2 balance during myogenesis via
ERK1/2 by reducing MMP-9 expression. Of note, it would
be of interest to explore the relative ratio between MMPs
and tissue inhibitors of MMPs (TIPMs), as there is no
available data about this mode of regulation during muscle
inflammation and regeneration involving IL-17, although
there are some reports about their mutual regulation during
muscle differentiation [40].
Finally, in Duchenne muscular dystrophy (DMD), pri-
mary deficiency of dystrophin leads to several secondary
pathological changes including ECM breakdown, inflamma-
tion, and fibrosis, all of which require MMP activity. Besides
revealing that MMP-9 inhibition augments the prolifera-
tion of satellite cells and changes the immune cell milieu
as well as expression of significant ligands, receptors, and
signaling pathways, this group showed that inhibition of
MMP-9 dramatically improves the engraftment of trans-
planted myoblasts in skeletal muscle of mdx mice (a mouse
model of DMD) [42]. Together with our results, this finding
adds value to the importance of MMP-9 in muscle regenera-
tion and suggests this enzyme as a possible target in muscle
regeneration and repair.
However, the effect of IL-17 in the regulation of MMP-
9 production in myoblast cells and its association with
physiological events and/or pathological conditions as well as
Doxycycline inhibition of IL-17-induced MMP-9 expression
should be additionally confirmed in further in vivo studies,
as this will help determine its role in muscle disease and
regeneration.
5. Conclusions
Our data provide evidence that Doxycycline inhibits the
capacity of IL-17 to induce MMP-9 expression in myoblast
cells by regulating the activation of ERK1/2 parallel with its
ability to protect C2C12 myoblast cells from the inhibitory
effect that IL-17 has on myogenic differentiation. The regu-
lation of IL-17–induced MMP-9 expression by Doxycycline
may be useful to control the proteolytic status during muscle
regeneration and muscle inflammatory diseases.
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